|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000124215 |
Summary for CDH26 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000124215 | Gene symbol | CDH26 |
| Gene name | cadherin 26 | |
| HGNC | 15902 | |
| Entrez ID | 60437 | |
| Gene type | protein_coding | |
| Synonyms | CDH26|VR20 | |
| UniProtAcc | Q8IXH8 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CDH26 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CDH26 | 8.76e+02 | 2.73e+00 | 6.27e-01 | 4.35e+00 | 1.37e-05 | 7.81e-05 | BLCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for CDH26 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CDH26 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg14115220 | chr20:59958366 | CGI:chr20:59939016-59940581 | promoter | 6.27e-01 | 4.70e-01 | 2.07e+00 | 3.84e-02 | 4.52e-02 | 1.57e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg20895028 | chr20:59958388 | CGI:chr20:59939016-59940581 | promoter | 7.36e-01 | 8.70e-01 | -3.12e+00 | 1.79e-03 | 3.17e-03 | -1.34e-01 |
| LUSC | cg14115220 | chr20:59958366 | CGI:chr20:59939016-59940581 | promoter | 6.93e-01 | 8.97e-01 | -2.65e+00 | 8.01e-03 | 1.17e-02 | -2.04e-01 |
| LUSC | cg20895028 | chr20:59958388 | CGI:chr20:59939016-59940581 | promoter | 6.66e-01 | 8.50e-01 | -2.47e+00 | 1.36e-02 | 1.76e-02 | -1.84e-01 |
| LUSC | cg24607535 | chr20:59958440 | CGI:chr20:59939016-59940581 | UTR,promoter,exon,gene body | 7.15e-01 | 8.91e-01 | -2.52e+00 | 1.19e-02 | 1.58e-02 | -1.76e-01 |
| COAD | cg25325053 | chr20:59957967 | CGI:chr20:59939016-59940581 | promoter | 3.27e-01 | 6.38e-01 | -2.71e+00 | 6.74e-03 | 1.05e-02 | -3.11e-01 |
| BLCA | cg14115220 | chr20:59958366 | CGI:chr20:59939016-59940581 | promoter | 5.81e-01 | 7.80e-01 | -2.49e+00 | 1.29e-02 | 1.73e-02 | -1.99e-01 |
| BLCA | cg20895028 | chr20:59958388 | CGI:chr20:59939016-59940581 | promoter | 5.81e-01 | 7.61e-01 | -2.33e+00 | 2.00e-02 | 2.45e-02 | -1.80e-01 |
| BLCA | cg24607535 | chr20:59958440 | CGI:chr20:59939016-59940581 | UTR,promoter,exon,gene body | 5.86e-01 | 7.74e-01 | -2.19e+00 | 2.86e-02 | 3.24e-02 | -1.88e-01 |
| LIHC | cg25325053 | chr20:59957967 | CGI:chr20:59939016-59940581 | promoter | 5.32e-01 | 6.79e-01 | 2.65e+00 | 8.10e-03 | 1.01e-02 | -1.47e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg25325053 | chr20:59957967 | CGI:chr20:59939016-59940581 | promoter | 6.04e-01 | 8.88e-01 | -2.95e+00 | 3.13e-03 | 3.82e-03 | -2.84e-01 |
| BRCA | cg14115220 | chr20:59958366 | CGI:chr20:59939016-59940581 | promoter | 6.27e-01 | 8.98e-01 | -1.06e+01 | 3.41e-26 | 3.26e-25 | -2.71e-01 |
| BRCA | cg20895028 | chr20:59958388 | CGI:chr20:59939016-59940581 | promoter | 6.66e-01 | 8.64e-01 | -9.47e+00 | 2.72e-21 | 1.64e-20 | -1.98e-01 |
| BRCA | cg24607535 | chr20:59958440 | CGI:chr20:59939016-59940581 | UTR,promoter,exon,gene body | 6.98e-01 | 9.19e-01 | -1.05e+01 | 8.19e-26 | 7.53e-25 | -2.22e-01 |
| HNSC | cg14115220 | chr20:59958366 | CGI:chr20:59939016-59940581 | promoter | 8.58e-01 | 6.69e-01 | 2.87e+00 | 4.07e-03 | 1.23e-02 | 1.89e-01 |
| HNSC | cg20895028 | chr20:59958388 | CGI:chr20:59939016-59940581 | promoter | 8.24e-01 | 6.80e-01 | 2.67e+00 | 7.60e-03 | 1.62e-02 | 1.44e-01 |
| HNSC | cg24607535 | chr20:59958440 | CGI:chr20:59939016-59940581 | UTR,promoter,exon,gene body | 8.55e-01 | 7.45e-01 | 2.41e+00 | 1.60e-02 | 2.42e-02 | 1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for CDH26 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CDH26 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CDH26 |
| TFs related to CDH26. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| MESO | ARGFX | CDH26 | 4.46e+00 | 9.87e-01 | 3.09e+00 | 5.76e-03 | Male-biased |
| MESO | ISX | CDH26 | 4.25e+00 | 9.85e-01 | 2.85e+00 | 5.14e-03 | Male-biased |
| READ | IRX3 | CDH26 | 4.38e+00 | 9.83e-01 | 3.48e+00 | 7.00e-03 | Male-biased |
| READ | ZNF211 | CDH26 | 5.15e+00 | 9.87e-01 | 4.32e+00 | 9.79e-03 | Male-biased |
| SARC | ARGFX | CDH26 | 4.39e+00 | 9.91e-01 | 3.38e+00 | 7.60e-04 | Male-biased |
| SARC | DUX4 | CDH26 | 4.35e+00 | 9.89e-01 | 3.53e+00 | 2.15e-03 | Male-biased |
| SARC | DUXA | CDH26 | 4.31e+00 | 9.87e-01 | 3.53e+00 | 2.79e-03 | Male-biased |
| SARC | GATA3 | CDH26 | 4.35e+00 | 9.88e-01 | 3.55e+00 | 2.46e-03 | Male-biased |
| SARC | GATA5 | CDH26 | 4.76e+00 | 9.90e-01 | 4.09e+00 | 4.90e-03 | Male-biased |
| SARC | GATA6 | CDH26 | 4.82e+00 | 9.92e-01 | 4.08e+00 | 3.37e-03 | Male-biased |
| SARC | GSX1 | CDH26 | 4.37e+00 | 9.89e-01 | 3.54e+00 | 2.06e-03 | Male-biased |
| SARC | IRX3 | CDH26 | 4.44e+00 | 9.90e-01 | 3.61e+00 | 1.95e-03 | Male-biased |
| SARC | ISX | CDH26 | 4.25e+00 | 9.88e-01 | 3.27e+00 | 8.60e-04 | Male-biased |
| SARC | MEF2B | CDH26 | 4.16e+00 | 9.84e-01 | 3.42e+00 | 3.32e-03 | Male-biased |
| SARC | ZBTB33 | CDH26 | 5.06e+00 | 9.91e-01 | 4.42e+00 | 6.07e-03 | Male-biased |
| SARC | ZNF211 | CDH26 | 5.18e+00 | 9.95e-01 | 4.42e+00 | 3.02e-03 | Male-biased |
| UVM | ZNF418 | CDH26 | 4.96e+00 | 9.80e-01 | 3.72e+00 | 1.16e-02 | Male-biased |
| CDH26 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CDH26 |
| RBPs related to ES in CDH26. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CDH26 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs12624389 | chr20:54103930:G:T | - | 0.161030633770777 | 0.00819236085795971 | BLCA | Female-baised eQTL |
| rs4811844 | chr20:57418499:G:A | - | 0.060540629042176 | 0.000487982239444963 | LUAD | Female-baised eQTL |
| rs6513497 | chr20:60308547:T:G | - | 0.0676386164410463 | 0.0052706775845101 | LUAD | Female-baised eQTL |
| rs73623771 | chr20:60315944:G:A | - | 0.0797414880089099 | 0.00614038100562657 | LUAD | Female-baised eQTL |
| rs6025139 | chr20:56756264:T:G | - | 0.0374984448200415 | 0.0232218146978699 | LUAD | Female-baised eQTL |
| rs6025142 | chr20:56756940:C:T | - | 0.0373968336282474 | 0.0234175375794244 | LUAD | Female-baised eQTL |
| rs6069656 | chr20:56224751:A:T | - | -0.0543526740170156 | 0.0256523034361592 | LUAD | Female-baised eQTL |
| rs4811678 | chr20:56225976:C:A | - | -0.0539614109437817 | 0.027661835464727 | LUAD | Female-baised eQTL |
| rs4811680 | chr20:56226159:A:G | - | -0.0539614109437817 | 0.027661835464727 | LUAD | Female-baised eQTL |
| rs4811677 | chr20:56225947:G:C | - | -0.051117264770615 | 0.0377430502963293 | LUAD | Female-baised eQTL |
| rs4811681 | chr20:56226316:G:A | - | -0.0513091677700249 | 0.0396965581825414 | LUAD | Female-baised eQTL |
| rs74867749 | chr20:52395462:T:A | - | 0.0489522268035978 | 0.0451028205236612 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs62205860 | chr20:58232258:C:T | - | 0.111448024036358 | 0.0353419919819648 | LUAD | Male-baised eQTL |
| rs62204359 | chr20:58228969:T:G | - | 0.107156317403465 | 0.0460915684205424 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000124215 |
| CpG Site: cg20895028 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.29218731420036 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg20895028 | chr20:59958388 | promoter | -0.29218731420036 | 7.29440637154578e-06 | -0.3456093537635368 | 1.4495969914328537e-08 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CDH26 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
